What Brighten Optix does

Brighten Optix (亨泰光學) is a Taiwan-based ophthalmic goods manufacturer founded in 1976, headquartered in Taipei. The company produces hard contact lenses, corneal plastic films, and related products, with a specialty focus on myopia control lenses designed to slow myopia progression in children and adults and to enhance visual performance. Its core technology is concentrated in contact lens design and fabrication for vision correction and myopia management, rather than in software, electronics, or AI-driven products.

The company operates a B2B2C distribution model, reaching end consumers through two primary channels: medical institutions (hospitals and clinics that recommend and dispense lenses to patients) and eyewear retailers (optical stores selling lenses to consumers). Its customer base is concentrated in Taiwan, with no demonstrated international sales footprint prior to the 2024 acquisition. The website copy emphasizes collaboration with medical institutions and eyewear channels under the brand positioning of being 'a visual performance company.'

In 2024, Brighten Optix was acquired by Carl Zeiss AG for NT$5.4 billion (approximately US$165 million), making it a wholly-owned subsidiary of the German optics and photonics group. Following the acquisition, ZEISS announced plans to expand R&D teams in Hsinchu by at least 50% and to leverage Brighten Optix within its broader strategy spanning medical optics, semiconductor inspection, and advanced optical technologies. The company is privately held and currently operates with 101-250 employees, with detailed revenue not publicly disclosed.

Name

Brighten Optix

Legal name

Brighten Optix Corp (亨泰光學)

Website

https://brightenoptix.com.tw

Company type

Private

Founded year

1976

Operating status

Acquired

Headcount range

51–100 employees

Short description

Brighten Optix is a Taiwan-based contact lens manufacturer founded in 1976, specializing in myopia control and visual performance lenses distributed through medical institutions and eyewear retailers, now a wholly-owned subsidiary of Carl Zeiss AG following its 2024 acquisition.

Ownership category

akta.pro rank

Product category

Ophthalmic Contact Lenses

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)

akta.pro secondary industry

Contact Lens Specialty & Myopia Control (HLAKAKAK)

Keywords

• Ophthalmic contact lenses
• Myopia control lenses
• Vision correction products
• Corneal plastic films
• Contact lens manufacturing

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contact Lens Sales: Sale of contact lenses for visual performance and myopia control applications

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Brighten Optix (亨泰光學) manufactures ophthalmic goods including hard contact lenses and corneal plastic films, with a specialization in myopia control lenses and visual performance enhancement products. The company supplies its contact lens products to medical institutions (hospitals and clinics) and eyewear retailers across Taiwan, who serve as distribution and recommendation channels for vision correction and myopia control treatments.

Product overview

Brighten Optix (亨泰光學) is a visual performance company that offers contact lenses, particularly specializing in myopia control lenses. The company operates as a single-product focused business, providing visual performance solutions through contact lenses to medical institutions and eyewear retailers. The company was acquired by Carl Zeiss AG in 2024 for NT$5.4 billion, expanding Zeiss's advanced optics portfolio in the semiconductor and optical technology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Myopia Control Contact Lenses Specialized contact lenses designed for myopia control and visual performance enhancement, addressing myopia progression particularly in children. Sold through medical institutions and eyewear retailers in Taiwan.
• Hard Contact Lenses Hard (rigid gas permeable) contact lenses for vision correction, serving patients with refractive errors through hospitals, clinics, and optical retail channels in Taiwan.
• Corneal Plastic Films Ophthalmic corneal plastic films manufactured by Brighten Optix as part of its ophthalmic goods product line. Used in clinical vision correction applications and supplied through medical channels.

Quantifiable outcome

• Taiwan myopia control lenses market growing from US$49.30 million (2024) to US$140.60 million (2033)

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Carl Zeiss AGflagshipStrategic or Co-development Partner · 24 March 2026Carl Zeiss AG acquired Brighten Optix Corp for NT$5.4 billion as part of its strategic expansion into advanced chip manufacturing, packaging inspections, and optical technology. ZEISS plans to expand R&D teams by at least 50% in Hsinchu as part of its long-term investment plan. The acquisition provides Brighten Optix with access to Zeiss's global resources and advanced optics capabilities.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Bausch + Lomb: Bausch + Lomb is a major global contact lens and ophthalmic goods manufacturer with brands including Biotrue and Ultra. Comparable to Brighten Optix in manufacturing contact lenses and serving vision correction consumers through medical and retail channels.
• CooperVision: CooperVision is one of the world's leading soft contact lens manufacturers with a strong myopia management portfolio (MiSight). Directly comparable to Brighten Optix in myopia control contact lenses and B2B2C distribution through eye care professionals.
• Johnson & Johnson Vision: Johnson & Johnson Vision, through its Acuvue brand, is one of the world's largest contact lens manufacturers with a broad portfolio including myopia management lenses. Directly comparable to Brighten Optix in core contact lens technology and vision correction end markets, though at vastly larger scale and global reach.
• Alcon: Alcon is a global leader in eye care with a major contact lens and surgical/ophthalmic franchise. Highly comparable to Brighten Optix as a contact lens and vision care specialist operating at global scale, with overlapping myopia management and specialty lens offerings.

Direct peers

• Menicon: Menicon is a Japan-based specialty contact lens manufacturer with deep expertise in orthokeratology and myopia control lenses. Closely comparable to Brighten Optix as a regional specialist in hard/RGP contact lenses and myopia management, serving similar medical institution and optical retail channels in Asia.
• HOYA Corporation: HOYA Corporation operates a significant ophthalmic lens and contact lens business across Asia and globally. Comparable to Brighten Optix in ophthalmic lens manufacturing and as a Japan/Asia-based vision care company with overlapping product categories and distribution models.
• Paragon Vision Sciences: Paragon Vision Sciences is a specialty contact lens manufacturer known for orthokeratology and corneal reshaping lenses used in myopia control. Directly comparable to Brighten Optix in specialty/hard contact lens technology and myopia management end markets.

Emerging players

• Euclid Systems Corporation: Euclid Systems is a specialty contact lens company focused on orthokeratology and myopia management lenses. Comparable to Brighten Optix as a niche player in myopia control lens technology targeting the same clinical and pediatric patient segments.
• Visioneering Technologies: Visioneering Technologies is a US-based specialty contact lens company focused on myopia management and presbyopia solutions. Comparable to Brighten Optix as a smaller-scale specialist in vision performance and myopia control lenses sold through eye care professionals.

Others

• Carl Zeiss Meditec: Carl Zeiss Meditec is the medical technology arm of Carl Zeiss AG, Brighten Optix's parent company, focused on ophthalmic diagnostic and surgical equipment. Adjacent parent-company ecosystem player that shares ophthalmic end markets and now provides distribution, R&D, and capital backing to Brighten Optix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brighten Optix